Condition
SAR-CoV-2
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
P 3 (1)
Trial Status
Completed2
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT07314905Phase 3Not Yet Recruiting
Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)
NCT07049497CompletedPrimary
Study of Immune Response in Subjects Vaccinated Against SARS-CoV-2 Infection
NCT05220514Completed
Long-term Effects of COVID-19
Showing all 3 trials